ImaSight Inc. Competitors

Siemens Healthineers is a leading medtech company with over 125 years of experience. We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Our portfolio, spanning in vitro and in vivo diagnostics to image-guided therapy and cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the greatest challenges in healthcare. We will continue to build on these strengths to help overcome the world’s most threatening diseases, enable efficient operations, and expand access to care. We are a team of more than 71,000 Healthineers in over 70 countries passionately pushing the boundaries of what is possible in healthcare to help improve the lives of people around the world.

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling almost 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets (September 30, 2025). For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses, and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare, and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future. With over 46,600 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 30 production facilities worldwide. Learn more about ZEISS: www.zeiss.com/about Data privacy: www.zeiss.com/data-protection Imprint: www.zeiss.com/publisher This is ZEISS's official LinkedIn account. It follows the ZEISS Netiquette: www.zeiss.com/netiquette

Each year, millions of people hear the words no one wants to hear: "You have cancer." And behind each diagnosis lies a unique story, a family that deserves hope, a future that's worth fighting for. We know that no two treatment journeys are the same and delivering care is far from simple. It's complex, urgent, and deeply human. That’s why we don’t back down from challenges—we rise to them. From the smallest tumor change to the toughest clinical decisions, we see every obstacle as an opportunity to progress. That is what drives us. The people undergoing treatment. The clinicians providing the care. We are united in purpose. Together, we can create a world where every patient has access to the highest standard of care. This is our commitment because for everyone, it's personal. We are leading the innovation in personalized radiation therapy solutions. We are Elekta. Elekta reserves the right to remove any comment and to restrict access to its page at its sole discretion, without prior notice. The presence of user comments does not imply endorsement by Elekta, and Elekta makes no representations regarding the accuracy of such comments. User-generated content does not necessarily reflect the views, values, or positions of Elekta.